A bevy of transactions in the pharmaceutical industry and industrial sector in Europe helped make the past week a big one for M&A, with more than a dozen billion-dollar deals being announced.
Israel’s Teva Pharmaceutical Industries Ltd. turned to Sullivan & Cromwell to advise on its $40.5 billion acquisition of the generic drug business of Dublin-based Allergan, represented by Latham & Watkins. As noted by The Am Law Daily earlier this week, the deal effectively pulled the plug on Teva’s hostile bid for fellow generic drug maker Mylan NV, which had not fared well.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
